<DOC>
	<DOCNO>NCT00539734</DOCNO>
	<brief_summary>Age-related macular degeneration , lead cause blindness , cause abnormal growth vessel beneath retina . Ranibizumab ( Lucentis ) new drug inhibits growth new vessel recently approve FDA treat condition . This study carry evaluate change retinal function injection ranibizumab .</brief_summary>
	<brief_title>Changes Retinal Function After Intravitreal Ranibizumab Age-related Macular Degeneration</brief_title>
	<detailed_description>The functional change retina record electroretinography ( ERG ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age 45 year Clinical diagnosis wet AMD First injection ranibizumab protocol Best correct visual acuity 20/32 20/320 Consent form obtain Previously treat wet AMD patient Patients ocular disease cause abnormal ERG glaucoma , uveitis retinitis pigmentosa , etc . Pregnancy History seizure</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>age-related macular degeneration ( AMD )</keyword>
	<keyword>choroidal neovascularization membrane ( CNVM )</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>anti-vascular endothelial growth factor</keyword>
	<keyword>electrophysiology</keyword>
	<keyword>electroretinography</keyword>
</DOC>